Cargando…

1144. Modern Problem, Medieval Cure-Resistant Aeromonas in Medicinal Leeches

BACKGROUND: Medicinal leeches are used primarily in plastic and reconstructive surgery when venous congestion threatens tissue viability. The associated infection risk ranges from 4.1 to 20%. Prophylactic antimicrobials such as fluoroquinolones (FQ) or trimethoprim-sulfamethoxazole (SXT) are recomme...

Descripción completa

Detalles Bibliográficos
Autores principales: Parkes, Leighanne Olivia, Barker, Kevin, Poutanen, Susan M, Grant, Jennifer M, Libman, Michael, Leis, Jerome, Stapleton, Patrick, Silverman, Michael, Hota, Susy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253417/
http://dx.doi.org/10.1093/ofid/ofy210.977
_version_ 1783373489440292864
author Parkes, Leighanne Olivia
Barker, Kevin
Poutanen, Susan M
Grant, Jennifer M
Libman, Michael
Leis, Jerome
Stapleton, Patrick
Silverman, Michael
Hota, Susy
author_facet Parkes, Leighanne Olivia
Barker, Kevin
Poutanen, Susan M
Grant, Jennifer M
Libman, Michael
Leis, Jerome
Stapleton, Patrick
Silverman, Michael
Hota, Susy
author_sort Parkes, Leighanne Olivia
collection PubMed
description BACKGROUND: Medicinal leeches are used primarily in plastic and reconstructive surgery when venous congestion threatens tissue viability. The associated infection risk ranges from 4.1 to 20%. Prophylactic antimicrobials such as fluoroquinolones (FQ) or trimethoprim-sulfamethoxazole (SXT) are recommended and target commonly isolated pathogen and gut symbiont, Aeromonas. However, resistance to these agents has been reported and detected in leeches, including at hospital systems across Canada that acquire their stock from the same supplier. Our objective was to describe the local epidemiology of leech-related Aeromonas resistant to one or more commonly used prophylactic agents, and determine if such resistance originates from the common supplier. METHODS: Six hospital systems across Canada using leech therapy, purchased from the same supplier, were surveyed. A 5-year retrospective review of all antimicrobial resistant leech-related Aeromonas, derived from clinical, leech, and tank fluid specimens was performed. All Aeromonas resistant to either FQ or SXT were included, and retained frozen isolates from each system were analysed by pulse-field gel electrophoresis (PFGE) using a published Aeromonas protocol. RESULTS: All six hospital systems reported leech-related Aeromonas resistant to one or more antimicrobials, totalling 15 isolates. Three systems only reported data from the last year. Four systems used FQ and two used SXT as prophylaxis. Fifteen of 15 were either FQ resistant or intermediate, and four of 15 were SXT resistant. Three of 10 isolates tested for ceftriaxone (CRO) susceptibility were resistant. Five of 15 of the isolates were resistant to two or more agents. Of the two leech quality control isolates, 2/2 were FQ resistant and 1/2 was FQ, SXT and CRO resistant. Only three isolates, each from a different, geographically distinct hospital system, had been retained. PFGE analysis indicated 2/3 are closely related (Figure 1). CONCLUSION: Our preliminary investigation suggests that the presence of FQ and SXT resistance in leech-related Aeromonas might be more common than previously suspected, and that such resistance might originate from a common source. A broader study of the molecular epidemiology of leech-related Aeromonas is warranted. [Image: see text] DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6253417
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62534172018-11-28 1144. Modern Problem, Medieval Cure-Resistant Aeromonas in Medicinal Leeches Parkes, Leighanne Olivia Barker, Kevin Poutanen, Susan M Grant, Jennifer M Libman, Michael Leis, Jerome Stapleton, Patrick Silverman, Michael Hota, Susy Open Forum Infect Dis Abstracts BACKGROUND: Medicinal leeches are used primarily in plastic and reconstructive surgery when venous congestion threatens tissue viability. The associated infection risk ranges from 4.1 to 20%. Prophylactic antimicrobials such as fluoroquinolones (FQ) or trimethoprim-sulfamethoxazole (SXT) are recommended and target commonly isolated pathogen and gut symbiont, Aeromonas. However, resistance to these agents has been reported and detected in leeches, including at hospital systems across Canada that acquire their stock from the same supplier. Our objective was to describe the local epidemiology of leech-related Aeromonas resistant to one or more commonly used prophylactic agents, and determine if such resistance originates from the common supplier. METHODS: Six hospital systems across Canada using leech therapy, purchased from the same supplier, were surveyed. A 5-year retrospective review of all antimicrobial resistant leech-related Aeromonas, derived from clinical, leech, and tank fluid specimens was performed. All Aeromonas resistant to either FQ or SXT were included, and retained frozen isolates from each system were analysed by pulse-field gel electrophoresis (PFGE) using a published Aeromonas protocol. RESULTS: All six hospital systems reported leech-related Aeromonas resistant to one or more antimicrobials, totalling 15 isolates. Three systems only reported data from the last year. Four systems used FQ and two used SXT as prophylaxis. Fifteen of 15 were either FQ resistant or intermediate, and four of 15 were SXT resistant. Three of 10 isolates tested for ceftriaxone (CRO) susceptibility were resistant. Five of 15 of the isolates were resistant to two or more agents. Of the two leech quality control isolates, 2/2 were FQ resistant and 1/2 was FQ, SXT and CRO resistant. Only three isolates, each from a different, geographically distinct hospital system, had been retained. PFGE analysis indicated 2/3 are closely related (Figure 1). CONCLUSION: Our preliminary investigation suggests that the presence of FQ and SXT resistance in leech-related Aeromonas might be more common than previously suspected, and that such resistance might originate from a common source. A broader study of the molecular epidemiology of leech-related Aeromonas is warranted. [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2018-11-26 /pmc/articles/PMC6253417/ http://dx.doi.org/10.1093/ofid/ofy210.977 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Parkes, Leighanne Olivia
Barker, Kevin
Poutanen, Susan M
Grant, Jennifer M
Libman, Michael
Leis, Jerome
Stapleton, Patrick
Silverman, Michael
Hota, Susy
1144. Modern Problem, Medieval Cure-Resistant Aeromonas in Medicinal Leeches
title 1144. Modern Problem, Medieval Cure-Resistant Aeromonas in Medicinal Leeches
title_full 1144. Modern Problem, Medieval Cure-Resistant Aeromonas in Medicinal Leeches
title_fullStr 1144. Modern Problem, Medieval Cure-Resistant Aeromonas in Medicinal Leeches
title_full_unstemmed 1144. Modern Problem, Medieval Cure-Resistant Aeromonas in Medicinal Leeches
title_short 1144. Modern Problem, Medieval Cure-Resistant Aeromonas in Medicinal Leeches
title_sort 1144. modern problem, medieval cure-resistant aeromonas in medicinal leeches
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253417/
http://dx.doi.org/10.1093/ofid/ofy210.977
work_keys_str_mv AT parkesleighanneolivia 1144modernproblemmedievalcureresistantaeromonasinmedicinalleeches
AT barkerkevin 1144modernproblemmedievalcureresistantaeromonasinmedicinalleeches
AT poutanensusanm 1144modernproblemmedievalcureresistantaeromonasinmedicinalleeches
AT grantjenniferm 1144modernproblemmedievalcureresistantaeromonasinmedicinalleeches
AT libmanmichael 1144modernproblemmedievalcureresistantaeromonasinmedicinalleeches
AT leisjerome 1144modernproblemmedievalcureresistantaeromonasinmedicinalleeches
AT stapletonpatrick 1144modernproblemmedievalcureresistantaeromonasinmedicinalleeches
AT silvermanmichael 1144modernproblemmedievalcureresistantaeromonasinmedicinalleeches
AT hotasusy 1144modernproblemmedievalcureresistantaeromonasinmedicinalleeches